+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sargramostim Market - Global Forecast 2025-2030- Product Image
Sargramostim Market - Global Forecast 2025-2030- Product Image
Sale

Sargramostim Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 181 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6130408
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Sargramostim is rapidly shaping the future of supportive care within hematology and oncology, exemplifying how innovation can enhance both patient outcomes and operational efficiency for healthcare providers worldwide. Positioned at the intersection of clinical need, regulatory evolution, and supply chain resilience, this market is attracting sustained interest from senior decision-makers seeking growth and competitive advantage.

Market Snapshot

The global sargramostim market is seeing strong-forward momentum, fueled by increasing demand for therapies that shorten recovery times and improve infection control following intensive treatments such as chemotherapy and stem cell transplantation. With enhanced adoption in established regions due to robust reimbursement structures and a deepening footprint in emerging markets, the market’s expansion is shaped by ongoing advancements in production technologies and the entry of biosimilar candidates. This has resulted in a dynamic competitive environment characterized by simultaneous cost pressures and quality improvements, prompting stakeholders to reassess growth strategies in both mature and developing healthcare systems.

Sargramostim Market Scope & Segmentation

  • Indication: Chemotherapy-induced neutropenia, infection prophylaxis, stem cell transplant support
  • Route of Administration: Intravenous, subcutaneous
  • Distribution Channel: Hospital pharmacy (inpatient, outpatient), retail pharmacy, specialty clinic
  • Dose Form: Prefilled syringe, single-dose vial
  • End User: Home care, academic hospital, community hospital, specialty clinic
  • Patient Age Group: Adult, pediatric
  • Mode of Therapy: Combination therapy, monotherapy
  • Regions Analyzed: Americas (United States—California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (comprising China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Industry Participants: Partner Therapeutics, Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Biocon Ltd., Intas Pharmaceuticals Ltd., Celltrion, Inc., Fresenius Kabi AG, Dr. Reddy’s Laboratories Ltd., Cadila Healthcare Ltd.
  • Technological Innovations: Single-use bioreactor platforms, continuous purification, prefilled syringes, digital health integrations, biosimilar development, smart injection and adherence tracking

Key Takeaways

  • Recent years have witnessed the evolution of sargramostim from infection risk mitigation to broader supportive care, aligning with patient-centric recovery pathways in modern healthcare.
  • Innovations in both upstream manufacturing and downstream formulation, such as prefilled syringes and remote monitoring, are improving therapy adoption—especially in outpatient and home care settings.
  • Biosimilar entry is generating downward pressure on pricing while prompting original manufacturers to refine their value propositions and clinical support models.
  • Market adoption is closely tied to local regulatory agility, payer engagement, and technology adaptation—requiring tailored go-to-market approaches for each region and channel.
  • Expanded clinical indications and advancements in individualized dosing reinforce sargramostim’s relevance as precision medicine and real-world evidence play a larger role in treatment decisions.

Tariff Impact

The introduction of new United States tariffs in 2025 has directly influenced sargramostim supply chains, particularly through higher active pharmaceutical ingredient costs and increased logistics expenses. Manufacturers are actively revising sourcing strategies by negotiating long-term supplier agreements and exploring domestic production avenues to reduce exposure to volatile duties. These changes are reverberating throughout distribution and affecting inventory management, contract renegotiations, and patient access, underscoring the importance of transparent communication and agile operations for all stakeholders.

Methodology & Data Sources

This report is grounded in a rigorous combination of secondary research—including peer-reviewed literature, clinical trials, regulatory documents, and industry white papers—paired with primary insights from expert interviews and targeted surveys. All quantitative data have undergone cross-validation and sensitivity testing, with findings benchmarked against authoritative industry and health agency reports for reliability.

Why This Report Matters

  • Delivers actionable intelligence for strategic planning amid evolving technology, reimbursement, and competition in the sargramostim segment.
  • Enables senior leaders to optimize investments and operational decisions by understanding tariff impacts, supply chain risks, and new therapeutic opportunities.
  • Facilitates cross-functional alignment—across procurement, clinical, and strategy teams—with an analytical foundation rooted in real-world market dynamics.

Conclusion

The sargramostim market is navigating a period of transformation marked by technological advances, biosimilar competition, and operational recalibration. Decision-makers equipped with this report can anticipate market evolution, align organizational priorities, and enhance resilient patient care strategies.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increased development of sargramostim biosimilars driving pricing competition and market access
5.2. Expanded clinical trials exploring sargramostim combination therapies in solid tumor immuno-oncology
5.3. Growing interest in sargramostim for wound healing and dermatological uses in regenerative medicine
5.4. Regulatory approvals in emerging markets accelerating sargramostim adoption for postchemotherapy support
5.5. Strategic partnerships between biotech firms and contract manufacturers to optimize sargramostim supply chain
5.6. Cost containment pressures leading to value-based contracting and outcomesbased pricing for sargramostim
5.7. Expanded reimbursement frameworks supporting outpatient administration of sargramostim injections
5.8. Integration of digital health tools to monitor patient response and adherence during sargramostim therapy
5.9. Advancements in formulary positioning influencing hospital uptake of sargramostim for neutropenia management
5.10. Ongoing research into sargramostim potential applications in COVID-19 induced acute respiratory distress syndrome
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Sargramostim Market, by Indication
8.1. Introduction
8.2. Chemotherapy-Induced Neutropenia
8.3. Infection Prophylaxis
8.4. Stem Cell Transplant Support
9. Sargramostim Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Subcutaneous
10. Sargramostim Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.2.1. Inpatient Pharmacy
10.2.2. Outpatient Pharmacy
10.3. Retail Pharmacy
11. Sargramostim Market, by Dose Form
11.1. Introduction
11.2. Prefilled Syringe
11.3. Single-Dose Vial
12. Sargramostim Market, by End User
12.1. Introduction
12.2. Home Care
12.3. Hospital
12.3.1. Academic Hospital
12.3.2. Community Hospital
12.4. Specialty Clinic
13. Sargramostim Market, by Patient Age Group
13.1. Introduction
13.2. Adult
13.3. Pediatric
14. Sargramostim Market, by Mode Of Therapy
14.1. Introduction
14.2. Combination Therapy
14.3. Monotherapy
15. Americas Sargramostim Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Sargramostim Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Sargramostim Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Partner Therapeutics, Inc.
18.3.2. Amgen Inc.
18.3.3. Teva Pharmaceutical Industries Ltd.
18.3.4. Sandoz International GmbH
18.3.5. Biocon Ltd.
18.3.6. Intas Pharmaceuticals Ltd.
18.3.7. Celltrion, Inc.
18.3.8. Fresenius Kabi AG
18.3.9. Dr. Reddy’s Laboratories Ltd.
18.3.10. Cadila Healthcare Ltd.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. SARGRAMOSTIM MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL SARGRAMOSTIM MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL SARGRAMOSTIM MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL SARGRAMOSTIM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SARGRAMOSTIM MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SARGRAMOSTIM MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS SARGRAMOSTIM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS SARGRAMOSTIM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC SARGRAMOSTIM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC SARGRAMOSTIM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. SARGRAMOSTIM MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. SARGRAMOSTIM MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. SARGRAMOSTIM MARKET: RESEARCHAI
FIGURE 30. SARGRAMOSTIM MARKET: RESEARCHSTATISTICS
FIGURE 31. SARGRAMOSTIM MARKET: RESEARCHCONTACTS
FIGURE 32. SARGRAMOSTIM MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. SARGRAMOSTIM MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SARGRAMOSTIM MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL SARGRAMOSTIM MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL SARGRAMOSTIM MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL SARGRAMOSTIM MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL SARGRAMOSTIM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL SARGRAMOSTIM MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL SARGRAMOSTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL SARGRAMOSTIM MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUTROPENIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL SARGRAMOSTIM MARKET SIZE, BY INFECTION PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL SARGRAMOSTIM MARKET SIZE, BY INFECTION PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL SARGRAMOSTIM MARKET SIZE, BY STEM CELL TRANSPLANT SUPPORT, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL SARGRAMOSTIM MARKET SIZE, BY STEM CELL TRANSPLANT SUPPORT, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL SARGRAMOSTIM MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL SARGRAMOSTIM MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL SARGRAMOSTIM MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL SARGRAMOSTIM MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL SARGRAMOSTIM MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL SARGRAMOSTIM MARKET SIZE, BY INPATIENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL SARGRAMOSTIM MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL SARGRAMOSTIM MARKET SIZE, BY OUTPATIENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL SARGRAMOSTIM MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL SARGRAMOSTIM MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL SARGRAMOSTIM MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL SARGRAMOSTIM MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL SARGRAMOSTIM MARKET SIZE, BY SINGLE-DOSE VIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL SARGRAMOSTIM MARKET SIZE, BY SINGLE-DOSE VIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL SARGRAMOSTIM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL SARGRAMOSTIM MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL SARGRAMOSTIM MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL SARGRAMOSTIM MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL SARGRAMOSTIM MARKET SIZE, BY ACADEMIC HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL SARGRAMOSTIM MARKET SIZE, BY ACADEMIC HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL SARGRAMOSTIM MARKET SIZE, BY COMMUNITY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL SARGRAMOSTIM MARKET SIZE, BY COMMUNITY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL SARGRAMOSTIM MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL SARGRAMOSTIM MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL SARGRAMOSTIM MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL SARGRAMOSTIM MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL SARGRAMOSTIM MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL SARGRAMOSTIM MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL SARGRAMOSTIM MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL SARGRAMOSTIM MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL SARGRAMOSTIM MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL SARGRAMOSTIM MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS SARGRAMOSTIM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS SARGRAMOSTIM MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS SARGRAMOSTIM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS SARGRAMOSTIM MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES SARGRAMOSTIM MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 107. CANADA SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 108. CANADA SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 109. CANADA SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. CANADA SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. CANADA SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. CANADA SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. CANADA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 114. CANADA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 115. CANADA SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2018-2024 (USD MILLION)
TABLE 116. CANADA SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2025-2030 (USD MILLION)
TABLE 117. CANADA SARGRAMOSTIM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. CANADA SARGRAMOSTIM MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. CANADA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 120. CANADA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 121. CANADA SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 122. CANADA SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 123. CANADA SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 124. CANADA SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 125. MEXICO SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 126. MEXICO SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 127. MEXICO SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 128. MEXICO SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 129. MEXICO SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. MEXICO SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. MEXICO SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 132. MEXICO SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 133. MEXICO SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2018-2024 (USD MILLION)
TABLE 134. MEXICO SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2025-2030 (USD MILLION)
TABLE 135. MEXICO SARGRAMOSTIM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. MEXICO SARGRAMOSTIM MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. MEXICO SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 138. MEXICO SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 139. MEXICO SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 140. MEXICO SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 141. MEXICO SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 142. MEXICO SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL SARGRAMOSTIM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL SARGRAMOSTIM MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA SARGRAMOSTIM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA SARGRAMOSTIM MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA SARGRAMOSTIM MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 206. UNITED KINGDOM SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2018-2024 (USD MILLION)
TABLE 208. UNITED KINGDOM SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM SARGRAMOSTIM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM SARGRAMOSTIM MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 217. GERMANY SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 218. GERMANY SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 219. GERMANY SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. GERMANY SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. GERMANY SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 222. GERMANY SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 223. GERMANY SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 224. GERMANY SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 225. GERMANY SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2018-2024 (USD MILLION)
TABLE 226. GERMANY SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2025-2030 (USD MILLION)
TABLE 227. GERMANY SARGRAMOSTIM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. GERMANY SARGRAMOSTIM MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. GERMANY SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 230. GERMANY SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 231. GERMANY SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 232. GERMANY SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 233. GERMANY SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 234. GERMANY SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 235. FRANCE SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 236. FRANCE SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 237. FRANCE SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. FRANCE SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. FRANCE SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. FRANCE SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. FRANCE SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 242. FRANCE SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 243. FRANCE SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2018-2024 (USD MILLION)
TABLE 244. FRANCE SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2025-2030 (USD MILLION)
TABLE 245. FRANCE SARGRAMOSTIM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. FRANCE SARGRAMOSTIM MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. FRANCE SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 248. FRANCE SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 249. FRANCE SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 250. FRANCE SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 251. FRANCE SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 252. FRANCE SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 253. RUSSIA SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 254. RUSSIA SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 255. RUSSIA SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. RUSSIA SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. RUSSIA SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. RUSSIA SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. RUSSIA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 260. RUSSIA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 261. RUSSIA SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2018-2024 (USD MILLION)
TABLE 262. RUSSIA SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA SARGRAMOSTIM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA SARGRAMOSTIM MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 271. ITALY SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 272. ITALY SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 273. ITALY SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. ITALY SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. ITALY SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. ITALY SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. ITALY SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 278. ITALY SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 279. ITALY SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2018-2024 (USD MILLION)
TABLE 280. ITALY SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2025-2030 (USD MILLION)
TABLE 281. ITALY SARGRAMOSTIM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. ITALY SARGRAMOSTIM MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. ITALY SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 284. ITALY SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 285. ITALY SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 286. ITALY SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 287. ITALY SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 288. ITALY SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 289. SPAIN SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 290. SPAIN SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 291. SPAIN SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. SPAIN SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. SPAIN SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. SPAIN SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. SPAIN SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 296. SPAIN SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 297. SPAIN SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2018-2024 (USD MILLION)
TABLE 298. SPAIN SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2025-2030 (USD MILLION)
TABLE 299. SPAIN SARGRAMOSTIM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. SPAIN SARGRAMOSTIM MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. SPAIN SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 302. SPAIN SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 303. SPAIN SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 304. SPAIN SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 305. SPAIN SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 306. SPAIN SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 315. UNITED ARAB EMIRATES SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2018-2024 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2025-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES SARGRAMOSTIM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES SARGRAMOSTIM MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 322. UNITED ARAB EMIRATES SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 323. UNITED ARAB EMIRATES SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 324. UNITED ARAB EMIRATES SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 325. SAUDI ARABIA SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 326. SAUDI ARABIA SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 327. SAUDI ARABIA SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 328. SAUDI ARABIA SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 329. SAUDI ARABIA SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 330. SAUDI ARABIA SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 331. SAUDI ARABIA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 332. SAUDI ARABIA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 333. SAUDI ARABIA SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2018-2024 (USD MILLION)
TABLE 334. SAUDI ARABIA SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2025-2030 (USD MILLION)
TABLE 335. SAUDI ARABIA SARGRAMOSTIM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 336. SAUDI ARABIA SARGRAMOSTIM MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 337. SAUDI ARABIA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 338. SAUDI ARABIA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 339. SAUDI ARABIA SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 340. SAUDI ARABIA SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 341. SAUDI ARABIA SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 342. SAUDI ARABIA SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 343. SOUTH AFRICA SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 344. SOUTH AFRICA SARGRAMOSTIM MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 345. SOUTH AFRICA SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 346. SOUTH AFRICA SARGRAMOSTIM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 347. SOUTH AFRICA SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 348. SOUTH AFRICA SARGRAMOSTIM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 349. SOUTH AFRICA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 350. SOUTH AFRICA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 351. SOUTH AFRICA SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2018-2024 (USD MILLION)
TABLE 352. SOUTH AFRICA SARGRAMOSTIM MARKET SIZE, BY DOSE FORM, 2025-2030 (USD MILLION)
TABLE 353. SOUTH AFRICA SARGRAMOSTIM MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 354. SOUTH AFRICA SARGRAMOSTIM MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 355. SOUTH AFRICA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 356. SOUTH AFRICA SARGRAMOSTIM MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 357. SOUTH AFRICA SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 358. SOUTH AFRICA SARGRAMOSTIM MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 359. SOUTH AFRICA SARGRAMOSTIM MARKET SIZE, BY MODE OF THERAPY, 2018-2024 (USD MILLION)
TABLE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Sargramostim market report include:
  • Partner Therapeutics, Inc.
  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Biocon Ltd.
  • Intas Pharmaceuticals Ltd.
  • Celltrion, Inc.
  • Fresenius Kabi AG
  • Dr. Reddy’s Laboratories Ltd.
  • Cadila Healthcare Ltd.

Related Topics

Related Reports

Neutropenia Biologic Drug Treatment Market Report 2025 - Product Image

Neutropenia Biologic Drug Treatment Market Report 2025

  • Report
  • 175 Pages
  • Global
From
IL-12 Receptor Antagonist Market - Global Forecast 2025-2030 - Product Image

IL-12 Receptor Antagonist Market - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
IL-1 Receptor Antagonist Market - Global Forecast 2025-2030 - Product Image

IL-1 Receptor Antagonist Market - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Vyvgart (Efgartigimod) Market Size, Share & Trends Analysis Report By Indication (Generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)), By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Vyvgart (Efgartigimod) Market Size, Share & Trends Analysis Report By Indication (Generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)), By Route of Administration, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From

About the Sargramostim Market

Sargramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) used to treat immune disorders. It is used to stimulate the production of white blood cells, which are important for fighting infection. It is used to treat neutropenia, a condition in which the body does not produce enough white blood cells, and to reduce the risk of infection in patients with HIV/AIDS. It is also used to treat certain types of cancer, such as leukemia and lymphoma, and to reduce the side effects of chemotherapy. Sargramostim is administered as an injection or intravenous infusion. It is available in both brand-name and generic forms. Common side effects include fever, chills, nausea, vomiting, and headache. The Sargramostim market is a growing segment of the immune disorders drugs market. It is used to treat a variety of conditions, including neutropenia, HIV/AIDS, and certain types of cancer. It is also used to reduce the side effects of chemotherapy. Some companies in the Sargramostim market include Amgen, Merck, Pfizer, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.